Thioredoxin prevents the development and progression of elastase-induced emphysema.
Thioredoxin 1 (TRX1) is a redox (reduction/oxidation)-active protein that scavenges reactive oxygen species. Here we examined whether endogenous or exogenous administration of TRX1 prevented the development and progression of elastase-induced pulmonary emphysema. Mice were treated with intratracheal elastase via microspray on day 0, and were given recombinant human TRX1 (rhTRX1) every other day from days -1 to 21. To determine the effects of TRX1 on the progression of established emphysema, mice were treated intratracheally with elastase on day 0, and rhTRX1 was administered from days 14 to 21. Histopathologic examination was performed on day 21. TRX1-transgenic but not transgene-negative mice demonstrated a decrease in the physiological indicators of elastase-induced emphysema. TRX1 administration from days -1 to 19 significantly decreased the signs of elastase-induced emphysema. Moreover, TRX1 administration beginning 14 days after elastase treatment significantly slowed the progression of emphysema. TRX1 may be of clinical benefit for the treatment of COPD.
Kinoshita
Takashi
T
Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Hoshino
Tomoaki
T
Imaoka
Haruki
H
Ichiki
Hiroko
H
Okamoto
Masaki
M
Kawayama
Tomotaka
T
Yodoi
Junji
J
Kato
Seiya
S
Aizawa
Hisamichi
H
D000818:Animals; D018450:Disease Progression; D004646:Emphysema / Q000139:chemically induced / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic; D010084:Oxidation-Reduction; D010196:Pancreatic Elastase; D029424:Pulmonary Disease, Chronic Obstructive / Q000517:prevention & control*; D011656:Pulmonary Emphysema / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D013879:Thioredoxins / Q000627:therapeutic use*; D013997:Time Factors
C515559:Txn1 protein, mouse; D013879:Thioredoxins; D010196:Pancreatic Elastase